Burmester, Gerd RBykerk, Vivian PBuch, Maya HTanaka, YoshiyaKameda, HidetoPraestgaard, Amyvan Hoogstraten, HubertFernandez-Nebro, AntonioHuizinga, Thomas2023-05-032023-05-032022http://hdl.handle.net/10668/19832Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs, such as MTX, has demonstrated improvement in clinical outcomes in patients with RA. The primary objective of this post hoc analysis was to compare the efficacy of sarilumab (200 mg every 2 weeks) monotherapy (MONARCH study) with that of sarilumab and MTX combination therapy (MOBILITY study) at week 24. The endpoints assessed were mean change from baseline in the Clinical Disease Activity Index (CDAI), 28-joint Disease Activity using CRP (DAS28-CRP), CRP, haemoglobin (Hb), pain visual analogue scale (VAS) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. Least square (LS) mean change from baseline (95% CI) at week 24 for all endpoints was compared between the treatment arms for adjusted comparisons. This analysis included 184 patients on sarilumab monotherapy and 399 patients on sarilumab plus MTX. Differences (P  This analysis demonstrated that the efficacy of sarilumab monotherapy was similar to that of sarilumab and MTX combination therapy.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/IL-6RiMOBILITYMONARCHcombination with MTXmonotherapyrheumatoid arthritissarilumabAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, RheumatoidDrug Therapy, CombinationFatigueHumansMethotrexatePainTreatment Outcomeresearch article34508594open access10.1093/rheumatology/keab6761462-0332PMC9157062https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keab676/40434877/keab676.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157062/pdf